User menu

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).

Bibliographic reference Dolusic, Eduard ; Frédérick, Raphaël. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).. In: Expert Opinion on Therapeutic Patents, Vol. 23, no.10, p. 1367-1381 (2013)
Permanent URL http://hdl.handle.net/2078.1/146379
  1. Uyttenhove Catherine, Pilotte Luc, Théate Ivan, Stroobant Vincent, Colau Didier, Parmentier Nicolas, Boon Thierry, Van den Eynde Benoît J, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, 10.1038/nm934
  2. Rafice Sara A., Chauhan Nishma, Efimov Igor, Basran Jaswir, Raven Emma Lloyd, Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase, 10.1042/bst0370408
  3. Sono Masanori, Roach Mark P., Coulter Eric D., Dawson John H., Heme-Containing Oxygenases, 10.1021/cr9500500
  4. Hwu P., Du M. X., Lapointe R., Do M., Taylor M. W., Young H. A., Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation, 10.4049/jimmunol.164.7.3596
  5. Platten M., Wick W., Van den Eynde B. J., Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion, 10.1158/0008-5472.can-12-0569
  6. Kudo Yoshiki, Boyd C.A.R, Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection, 10.1016/s0925-4439(99)00096-4
  7. Munn D. H., Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism, 10.1126/science.281.5380.1191
  8. Brandacher G., Prognostic Value of Indoleamine 2,3-Dioxygenase Expression in Colorectal Cancer: Effect on Tumor-Infiltrating T Cells, 10.1158/1078-0432.ccr-05-1966
  9. Okamoto A., Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells, 10.1158/1078-0432.ccr-04-2671
  10. Leung Benjamin S., Stout Lawrence E., Shaskan Edward G., Thompson Randall M., Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-γ in human gyneocologic cancer cells, 10.1016/0304-3835(92)90283-2
  11. Muller Alexander J, DuHadaway James B, Donover P Scott, Sutanto-Ward Erika, Prendergast George C, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy, 10.1038/nm1196
  12. Muller Alexander J, Malachowski William P, Prendergast George C, Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors, 10.1517/14728222.9.4.831
  13. Muller Alexander J., Prendergast George C., Marrying Immunotherapy with Chemotherapy: Why Say IDO?: Figure 1., 10.1158/0008-5472.can-05-2213
  14. Muller Alexander, Prendergast George, Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer, 10.2174/156800907780006896
  15. Pucchio Tiziana Di, Danese Silvio, Cristofaro Raimondo De, Rutella Sergio, Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds, 10.1517/13543770903512974
  16. C. Prendergast G., Y. Chang M., Mandik-Nayak L., Metz R., J. Muller A., Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases, 10.2174/092986711795656072
  17. Xu H., Oriss T. B., Fei M., Henry A. C., Melgert B. N., Chen L., Mellor A. L., Munn D. H., Irvin C. G., Ray P., Ray A., Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation, 10.1073/pnas.0708809105
  18. Grohmann U, Tolerance, DCs and tryptophan: much ado about IDO, 10.1016/s1471-4906(03)00072-3
  19. Kiank Cornelia, Zeden Jan-Philip, Drude Solveig, Domanska Grazyna, Fusch Gerhard, Otten Winfried, Schuett Christine, Psychological Stress-Induced, IDO1-Dependent Tryptophan Catabolism: Implications on Immunosuppression in Mice and Humans, 10.1371/journal.pone.0011825
  20. Ravishankar B., Liu H., Shinde R., Chandler P., Baban B., Tanaka M., Munn D. H., Mellor A. L., Karlsson M. C. I., McGaha T. L., Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase, 10.1073/pnas.1117736109
  21. Favre D., Mold J., Hunt P. W., Kanwar B., Loke P., Seu L., Barbour J. D., Lowe M. M., Jayawardene A., Aweeka F., Huang Y., Douek D. C., Brenchley J. M., Martin J. N., Hecht F. M., Deeks S. G., McCune J. M., Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease, 10.1126/scitranslmed.3000632
  22. FUCHS D., FORSMAN A., HAGBERG L., LARSSON M., NORKRANS G., REIBNEGGER G., WERNER E.R., WACHTER H., Immune Activation and Decreased Tryptophan in Patients with HIV-1 Infection, 10.1089/jir.1990.10.599
  23. Potula R., Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis, 10.1182/blood-2005-04-1403
  24. Pallotta Maria T, Orabona Ciriana, Volpi Claudia, Vacca Carmine, Belladonna Maria L, Bianchi Roberta, Servillo Giuseppe, Brunacci Cinzia, Calvitti Mario, Bicciato Silvio, Mazza Emilia M C, Boon Louis, Grassi Fabio, Fioretti Maria C, Fallarino Francesca, Puccetti Paolo, Grohmann Ursula, Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells, 10.1038/ni.2077
  25. Opitz Christiane A., Litzenburger Ulrike M., Sahm Felix, Ott Martina, Tritschler Isabel, Trump Saskia, Schumacher Theresa, Jestaedt Leonie, Schrenk Dieter, Weller Michael, Jugold Manfred, Guillemin Gilles J., Miller Christine L., Lutz Christian, Radlwimmer Bernhard, Lehmann Irina, von Deimling Andreas, Wick Wolfgang, Platten Michael, An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor, 10.1038/nature10491
  26. Pilotte L., Larrieu P., Stroobant V., Colau D., Dolusic E., Frederick R., De Plaen E., Uyttenhove C., Wouters J., Masereel B., Van den Eynde B. J., Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase, 10.1073/pnas.1113873109
  27. Madge D.J., Hazelwood R., Iyer R., Jones H.T., Salter M., Novel tryptophan dioxygenase inhibitors and combined tryptophan dioxygenase/5-HT reuptake inhibitors, 10.1016/0960-894x(96)00124-2
  28. Dolušić Eduard, Larrieu Pierre, Moineaux Laurence, Stroobant Vincent, Pilotte Luc, Colau Didier, Pochet Lionel, Van den Eynde Benoît, Masereel Bernard, Wouters Johan, Frédérick Raphaël, Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators, 10.1021/jm2006782
  29. Macchiarulo Antonio, Camaioni Emidio, Nuti Roberto, Pellicciari Roberto, Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease, 10.1007/s00726-008-0137-3
  30. Cady Susan G., Sono Masanori, 1-methyl-dl-tryptophan, β-(3-benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and β-[3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase, 10.1016/0003-9861(91)90142-6
  31. Eguchi Naomi, Watanabe Yasuyoshi, Kawanishi Kazuko, Hashimoto Yohei, Hayaishi Osamu, Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by β-carboline and indole derivatives, 10.1016/0003-9861(84)90579-4
  32. Dolušić Eduard, Larrieu Pierre, Blanc Sébastien, Sapunaric Frédéric, Norberg Bernadette, Moineaux Laurence, Colette Delphine, Stroobant Vincent, Pilotte Luc, Colau Didier, Ferain Thierry, Fraser Graeme, Galeni Moreno, Frère Jean-Marie, Masereel Bernard, Van den Eynde Benoît, Wouters Johan, Frédérick Raphaël, Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors, 10.1016/j.bmc.2010.12.032
  33. Dolušić E, Eur J Med Chem, 46, 3058 (2011)
  34. Brastianos Harry C., Vottero Eduardo, Patrick Brian O., Van Soest Rob, Matainaho Teatulohi, Mauk A. Grant, Andersen Raymond J., Exiguamine A, an Indoleamine-2,3-dioxygenase (IDO) Inhibitor Isolated from the Marine SpongeNeopetrosiaexigua, 10.1021/ja067211+
  35. Pereira Alban, Vottero Eduardo, Roberge Michel, Mauk A. Grant, Andersen Raymond J., Indoleamine 2,3-Dioxygenase Inhibitors from the Northeastern Pacific Marine HydroidGarveiaannulata, 10.1021/np060111x
  36. Banerjee T, DuHadaway J B, Gaspari P, Sutanto-Ward E, Munn D H, Mellor A L, Malachowski W P, Prendergast G C, Muller A J, A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase, 10.1038/sj.onc.1210939
  37. Gaspari Paul, Banerjee Tinku, Malachowski William P., Muller Alexander J., Prendergast George C., DuHadaway James, Bennett Shauna, Donovan Ashley M., Structure−Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors, 10.1021/jm0508888
  38. Carr Gavin, Chung Marco K. W., Mauk A. Grant, Andersen Raymond J., Synthesis of Indoleamine 2,3-Dioxygenase Inhibitory Analogues of the Sponge Alkaloid Exiguamine A, 10.1021/jm800143h
  39. Kumar Sanjeev, Malachowski William P., DuHadaway James B., LaLonde Judith M., Carroll Patrick J., Jaller Daniel, Metz Richard, Prendergast George C., Muller Alexander J., Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors, 10.1021/jm7014155
  40. Dolušić Eduard, Larrieu Pierre, Meinguet Céline, Colette Delphine, Rives Arnaud, Blanc Sébastien, Ferain Thierry, Pilotte Luc, Stroobant Vincent, Wouters Johan, Van den Eynde Benoît, Masereel Bernard, Delfourne Evelyne, Frédérick Raphaël, Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A, 10.1016/j.bmcl.2012.11.036
  41. Sono Masanori, Cady Susan G., Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands, 10.1021/bi00439a012
  42. Sugimoto H., Oda S.-i., Otsuki T., Hino T., Yoshida T., Shiro Y., Crystal structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase, 10.1073/pnas.0508996103
  43. Yue Eddy W., Douty Brent, Wayland Brian, Bower Michael, Liu Xiangdong, Leffet Lynn, Wang Qian, Bowman Kevin J., Hansbury Michael J., Liu Changnian, Wei Min, Li Yanlong, Wynn Richard, Burn Timothy C., Koblish Holly K., Fridman Jordan S., Metcalf Brian, Scherle Peggy A., Combs Andrew P., Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model, 10.1021/jm900518f
  44. Kumar Sanjeev, Jaller Daniel, Patel Bhumika, LaLonde Judith M., DuHadaway James B., Malachowski William P., Prendergast George C., Muller Alexander J., Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase, 10.1021/jm800512z
  45. Röhrig Ute F., Awad Loay, Grosdidier Aurélien, Larrieu Pierre, Stroobant Vincent, Colau Didier, Cerundolo Vincenzo, Simpson Andrew J. G., Vogel Pierre, Van den Eynde Benoît J., Zoete Vincent, Michielin Olivier, Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors, 10.1021/jm9014718
  46. Vottero Eduardo, Balgi Aruna, Woods Kate, Tugendreich Stuart, Melese Teri, Andersen Raymond J., Mauk A. Grant, Roberge Michel, Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast, 10.1002/biot.200600001
  47. Lob S., Konigsrainer A., Schafer R., Rammensee H.-G., Opelz G., Terness P., Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells, 10.1182/blood-2007-10-116111
  48. Qian F., Villella J., Wallace P. K., Mhawech-Fauceglia P., Tario J. D., Andrews C., Matsuzaki J., Valmori D., Ayyoub M., Frederick P. J., Beck A., Liao J., Cheney R., Moysich K., Lele S., Shrikant P., Old L. J., Odunsi K., Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer, 10.1158/0008-5472.can-08-2106
  49. Löb Stefan, Königsrainer Alfred, Zieker Derek, Brücher Björn L. D. M., Rammensee Hans-Georg, Opelz Gerhard, Terness Peter, IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism, 10.1007/s00262-008-0513-6
  50. Meininger David, Zalameda Leeanne, Liu Yichin, Stepan Lara P., Borges Luis, McCarter John D., Sutherland Claire L., Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors, 10.1016/j.bbapap.2011.07.023
  51. Metz R., DuHadaway J. B., Kamasani U., Laury-Kleintop L., Muller A. J., Prendergast G. C., Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound D-1-Methyl-Tryptophan, 10.1158/0008-5472.can-07-1872
  52. Yuasa Hajime J., Ball Helen J., Austin Christopher J.D., Hunt Nicholas H., 1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan, 10.1016/j.cbpb.2010.04.006
  53. Berthon Céline, Fontenay Michaela, Corm Selim, Briche Isabelle, Allorge Delphine, Hennart Benjamin, Lhermitte Michel, Quesnel Bruno, Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification, 10.1016/j.leukres.2013.02.001
  54. Dantzer Robert, O'Connor Jason C., Freund Gregory G., Johnson Rodney W., Kelley Keith W., From inflammation to sickness and depression: when the immune system subjugates the brain, 10.1038/nrn2297
  55. Schwarcz Robert, Bruno John P., Muchowski Paul J., Wu Hui-Qiu, Kynurenines in the mammalian brain: when physiology meets pathology, 10.1038/nrn3257
  56. Stone Trevor W, Darlington L Gail, The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders : Kynurenines and CNS disorders, 10.1111/bph.12230
  57. Stone Trevor W., Stoy Nicholas, Darlington L. Gail, An expanding range of targets for kynurenine metabolites of tryptophan, 10.1016/j.tips.2012.09.006
  58. Vécsei László, Szalárdy Levente, Fülöp Ferenc, Toldi József, Kynurenines in the CNS: recent advances and new questions, 10.1038/nrd3793
  59. Muller Alexander J., Scherle Peggy A., Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors, 10.1038/nrc1929
  60. Koblish H. K., Hansbury M. J., Bowman K. J., Yang G., Neilan C. L., Haley P. J., Burn T. C., Waeltz P., Sparks R. B., Yue E. W., Combs A. P., Scherle P. A., Vaddi K., Fridman J. S., Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors, 10.1158/1535-7163.mct-09-0628
  61. Miller Christine L, Llenos Ida C, Dulay Jeanette R, Barillo Meliza M, Yolken Robert H, Weis Serge, Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia, 10.1016/j.nbd.2003.12.015
  62. Wu Wei, Nicolazzo Joseph A., Wen Li, Chung Roger, Stankovic Roger, Bao Shisan S., Lim Chai K., Brew Bruce J., Cullen Karen M., Guillemin Gilles J., Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain, 10.1371/journal.pone.0059749
  63. Dolušić Eduard, Larrieu Pierre, Blanc Sébastien, Sapunaric Frédéric, Pouyez Jenny, Moineaux Laurence, Colette Delphine, Stroobant Vincent, Pilotte Luc, Colau Didier, Ferain Thierry, Fraser Graeme, Galleni Moreno, Frère Jean-Marie, Masereel Bernard, Van den Eynde Benoît, Wouters Johan, Frédérick Raphaël, Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors, 10.1016/j.ejmech.2011.02.049